Antibody-enhanced COVID-19 vaccination
Description of the granted funding
A major challenge in COVID-19 vaccinations is to induce robust and good-quality protective immunity, especially in older persons. We will use a clinically approved therapeutic antibodies to overcome these limitations in experimental models. By co-injecting small quantities of immunomodulatory antibodies with the with a vaccine antigen we will revive the COVID-19 vaccine responses in aged immune system, and re-direct the anti-vaccine immune response to the most beneficial protecting direction. Our conceptually new way of using accepted therapeutic antibodies as COVID-19 vaccine adjuvants has the potential to generate more effective vaccine responses with less adverse effects, substantial vaccine-sparing and the protection of older individuals.
Show moreStarting year
2020
End year
2022
Granted funding
Funder
Research Council of Finland
Funding instrument
Targeted Academy projects
Other information
Funding decision number
336422
Fields of science
Biomedicine
Research fields
Biolääketieteet
Themes
Lisätalousarvio III 2020
Identified topics
covid, pandemic, vaccines